Skip to main content

Table 1 Patient Demographics and MDS Disease Characteristics

From: Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)

Age (years)

 Median (range)

75 (57−82)

Age (years)

N (%)

 < 65 years

5 (26)

 ≥ 65 years

14 (74)

Gender

 Male

14 (74)

 Female

5 (26)

ECOG Performance Status

 0

13 (68)

 1

6 (32)

IPSS Classification

 Low Risk

5 (26)

 Intermediate-1 Risk

14 (74)

Baseline Cytogenetics

 Normal

14 (74)

 Abnormal

4 (21)

 Unknown

1 (5)

Transfusion Dependency

 RBC Transfusion Dependent

13 (68)

 Median (Range)

6 (4−10)

 Platelet Transfusion Dependent

2 (11)

WHO Classification

 RA

4 (21)

 RAEB-1

2 (11)

 RCMD

4 (21)

 RCMD-RS

5 (26)

 MDS-U

3 (16)

 MDS/MPD-U

1 (5)

Cell Lineage Cytopenia

 Unilineage Cytopenia

9 (47)

 Bilineage Cytopenia

6 (32)

 Trilineage Cytopenia

4 (21)

Baseline Cytopenia(s)

 Anemia only

9 (47)

 Anemia + Neutropenia

1 (5)

 Anemia + Thrombocytopenia

5 (26)

 Anemia + Neutropenia + Thrombocytopenia

4 (21)

Time from MDS Diagnosis (years)

 Median (range)

.9 (.10 − 2.5)

  1. Abbreviations: ECOG Eastern Cooperative Oncology Group; IPSS International Prognostic Scoring System; RBC red blood cell; RA refractory anemia; RAEB-1 RA with excess blasts, type 1; RCMD refractory cytopenia with multilineage dysplasia; RCMD-RS RCMD with ringed sideroblasts; MDS-U myelodysplastic syndrome-unclassified; MDS/MPN-U MDS/myeloproliferative neoplasm-unclassified.